TMPRSS2-ERG融合基因与转移性去势抵抗性前列腺癌化学药物治疗后生存率的关系

doi:10.3969/j.issn.1006-7795.2020.01.020

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (1): 103-107.doi: 10.3969/j.issn.1006-7795.2020.01.020

TMPRSS2-ERG融合基因与转移性去势抵抗性前列腺癌化学药物治疗后生存率的关系

谢英伟, 金仕鹏, 李爽, 王永辉, 王伟, 平浩, 刘跃新

首都医科大学附属北京同仁医院泌尿外科, 北京 100730

收稿日期:2019-06-11 出版日期:2020-02-21 发布日期:2020-02-13
通讯作者: 刘跃新 E-mail:doctorlyx@126.com
基金资助:
北京市自然科学基金（7102033）。

Correlation between TMPRSS2-ERG fusion gene and survival rate of metastatic castration-resistant prostate cancer after chemotherapy

Xie Yingwei, Jin Shipeng, Li Shuang, Wang Yonghui, Wang Wei, Ping Hao, Liu Yuexin

Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

Received:2019-06-11 Online:2020-02-21 Published:2020-02-13
Supported by:
This study was supported by Natural Science Foundation of Beijing (7102033).

摘要/Abstract

摘要： 目的明确TMPRSS2-ERG（T-E）融合基因与转移性去势抵抗性前列腺癌（metastatic castration-resistant prostate cancer，mCRPC）多西他赛化学药物治疗（以下简称化疗）后生存率的关系。方法选取首都医科大学附属北京同仁医院前列腺增生患者20例，前列腺癌化疗的患者50例。用实时定量聚合酶链反应（quantitative real time polymerase chain reaction，qRT-PCR）检查患者外周血单核细胞中融合基因表达。通过前列腺特异性抗原（prostate specific antigen，PSA）应答率、PSA-无进展生存率（free survival，PSA-PFS）、放射学无进展生存率（radiological progression free survival，RX-PFS）和总生存率（overall survival，OS）评估不同融合基因表达患者的治疗反应。结果 50例前列腺癌患者中10例（20%）检测到T-E融合基因。T-E阳性组的PSA应答率低于阴性组（32.52%vs 74.35%，P=0.040）。单因素生存分析显示T-E阳性患者前列腺PSA-PFS、RX-PFS、OS低于阴性患者，差异均有统计学意义（P < 0.01）。多因素Cox回归分析显示T-E阳性是PSA-PFS、RX-PFS和OS的独立危险因素（P=0.010，P=0.010，P=0.020）。结论 T-E融合基因表达是多西他赛化疗mCRPC患者PSA-PFS、RX-PFS和OS的独立危险因素。

关键词: TMPRSS2-ERG融合基因, 前列腺癌, 化学药物治疗, 耐药

Abstract: Objective To determine the correlation of TMPRSS2-ERG(T-E) fusion gene to the survival rate in metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Methods We included 20 patients with benign prostatic hyperplasia and 50 patients with prostate cancer(mCRPC) chemotherapy. The expression of T-E fusion gene in peripheral blood mononuclear cells was examined by quantitative real time polymerase chain reaction(qRT-PCR). Therapeutic responses of patients with different fusion gene expression were assessed by prostate specific antigen (PSA) response rate, PSA-progression free survival(PFS), radiological progression free survival(RX-PFS), and overall survival(OS). Results The T-E fusion gene was detected in 10 (20%) of 50 prostate cancer patients. The PSA response rate in the T-E positive group was lower than that in the negative group (32.52% vs 74.35%, P=0.040). Univariate survival analysis showed that PSA-PFS, RX-PFS, and OS were lower in T-E positive patients than in negative patients, and the difference was statistically significant (P<0.01). Multivariate Cox regression analysis showed that T-E positive was an independent risk factor for PSA-PFS, RX-PFS and OS (P=0.010, P=0.010, P=0.020). Conclusion This study demonstrates that T-E fusion gene expression is an independent risk factor for PSA-PFS, RX-PFS and OS in mCRPC patients treated with docetaxel.

Key words: TMPRSS2-ERG fusion gene, prostate cancer, chemotherapy, drug resistance

中图分类号:

R737.25

谢英伟, 金仕鹏, 李爽, 王永辉, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因与转移性去势抵抗性前列腺癌化学药物治疗后生存率的关系[J]. 首都医科大学学报, 2020, 41(1): 103-107.

Xie Yingwei, Jin Shipeng, Li Shuang, Wang Yonghui, Wang Wei, Ping Hao, Liu Yuexin. Correlation between TMPRSS2-ERG fusion gene and survival rate of metastatic castration-resistant prostate cancer after chemotherapy[J]. Journal of Capital Medical University, 2020, 41(1): 103-107.

参考文献

[1] Attard G,Parker C,Eeles R A,et al.Prostate cancer[J]. Lancet,2016,387:70-82.
[2] 中华医学会泌尿外科学分会,霍红梅,中国前列腺癌联盟.转移性前列腺癌化疗中国专家共识(2017版)[J].中华泌尿外科杂志,2017,38(3):161.
[3] Giacinti S,Carlini P,Roberto M,et al. Duration of response to first androgen deprivation therapy,time to castration resistance prostate cancer,and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate[J]. Anticancer Drugs,2016,28(1):1.
[4] 高晓芳,吴红茜,朱清毅,等.肿瘤微环境与前列腺癌化疗耐药的研究进展[J].药学研究,2016,35(2):104-107.
[5] 谢英伟,金世鹏,闫伟,等. TMPRSS2-ERG融合基因在淋巴结转移前列腺癌中的阳性率及与生存的关系[J].首都医科大学学报,2019,40(1):78-83.
[6] Scher HI,Halabi S,Tannock I,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone:recommendations of the Prostate Cancer Clinical Trials Working Group[J]. J Clin Oncol,2008,26(7):1148-1159.
[7] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):240-247.
[8] Chen W,Zheng R,Baade P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[9] Qi D,Wu C,Liu F,et al. Trends of prostate cancer incidence and mortality in Shanghai,China from 1973 to 2009[J]. Prostate,2015,75(14):1662-1668.
[10] Minner S,Enodien M,Sirma H,et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy[J]. Clin Cancer Res,2011,17(18):5878-5888.
[11] 陶晶,张豪杰,肖立,等. TMPRSS2-ERG融合基因在国人前列腺癌组织中的表达及其临床意义[J].中国男科学杂志,2016,30(12):16-20.
[12] Qi M,Yang X,Zhang F,et al. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients[J]. PLoS One,2014,9(2):e84959.
[13] Dong J,Xiao L,Sheng L,et al. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China[J]. Asian Pac J Cancer Prev,2014,15(7):3099-3103.
[14] Galletti G,Matov A,Beltran H,et al. ERG induces taxane resistance in castration-resistant prostate cancer[J]. Nat Commun,2014,5:5548.
[15] Reig Ò,Marín-Aguilera M,Carrera G,et al. TMPRSS2-ERG in blood and docetaxel resistance in metastatic castration-resistant prostate cancer[J]. Eur Urol,2016,70(5):709-713.
[16] Song W,Kwon G Y,Kim J H,et al. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer[J]. Oncotarget,2016,7(50):83735-83743.
[17] Marin-Aguilera M,Codony-Servat J,Reig O,et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer[J]. Mol Cancer Therapeut,2014,13(5):1270-1284.

TMPRSS2-ERG融合基因与转移性去势抵抗性前列腺癌化学药物治疗后生存率的关系

Correlation between TMPRSS2-ERG fusion gene and survival rate of metastatic castration-resistant prostate cancer after chemotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王文文, 蔡昱, 贾双双, 翟建军. 驱动蛋白家族成员2C与卵巢癌化学药物治疗耐药的相关性[J]. 首都医科大学学报, 2023, 44(1): 143-147.
[2]	钱芳, 姜利, 刘永东, 黄晶, 任燕明, 刘玉东, 李峨嵋, 原景, 裴爽, 赵延, 孙文秀, 禹利燕, 张晓萍, 张新梅, 王楠. 北京市西城区区属医院入院患者多重耐药菌快速筛查情况分析[J]. 首都医科大学学报, 2021, 42(6): 936-942.
[3]	蒋铭心, 苏瑶, 熊天宇, 叶小波, 靳松, 邢念增, 金木兰, 杨敏福, 牛亦农. 减瘤性根治性前列腺切除术对骨转移前列腺癌患者的临床疗效分析[J]. 首都医科大学学报, 2021, 42(6): 967-972.
[4]	王明帅, 熊天宇, 蒋铭心, 钱小松, 王思豪, 崔韵, 牛亦农. 改良前列腺尖部分离技术保留尿道周围结构对前列腺癌根治术后即刻尿控的影响[J]. 首都医科大学学报, 2021, 42(6): 973-977.
[5]	叶小波, 熊天宇, 崔韵, 王明帅, 杨辉, 安卓玲, 牛亦农. 醋酸阿比特龙联合强的松治疗去势抵抗型前列腺癌的疗效分析[J]. 首都医科大学学报, 2021, 42(6): 978-985.
[6]	樊笑琪, 刘志斌, 王明帅, 瓦斯里江·瓦哈甫, 宋黎明, 邢念增, 牛亦农. 腹腔镜单纯尿道前壁加强法与尿道前后壁加强法(Sandwich法)改善前列腺癌根治术后早期尿控的对比分析[J]. 首都医科大学学报, 2020, 41(4): 542-546.
[7]	白志杰, 王新胜, 马洪顺, 李波. mpMRI与超声融合导航技术在前列腺靶向穿刺的临床研究[J]. 首都医科大学学报, 2020, 41(4): 631-635.
[8]	平浩, 马林祥, 王明帅, 龙军, 牛亦农, 刘跃新, 邢念增. 单羧酸转运蛋白4(MCT4)在前列腺癌中的表达及调控研究[J]. 首都医科大学学报, 2019, 40(1): 59-64.
[9]	王蔚, 苏嘉明, 袁东波, 张伟, 陈卫红, 孙兆林, 朱建国. 微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系[J]. 首都医科大学学报, 2019, 40(1): 65-71.
[10]	谢英伟, 金世鹏, 闫伟, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因在淋巴结转移前列腺癌中的阳性率及与生存的关系[J]. 首都医科大学学报, 2019, 40(1): 72-77.
[11]	李东, 张树琛, 时琰丽, 李雪清, 鲁炳怀. 北京地区孕晚期妇女定植B族链球菌耐药状况与血清型分布情况分析[J]. 首都医科大学学报, 2018, 39(4): 591-595.
[12]	左灵坤, 阳荣辉, 马慧, 周萍, 孔璐. 生物信息学方法分析前列腺癌组织及细胞系中LMNA基因第七外显子点突变[J]. 首都医科大学学报, 2017, 38(6): 884-890.
[13]	赵倩, 金眉, 张大伟, 赵文, 张雪, 李刚, 冀园琦, 马晓莉. 4例同期治疗中进展的儿童髓母细胞瘤临床分析及经验总结[J]. 首都医科大学学报, 2017, 38(6): 925-929.
[14]	刘竞争, 郑光辉, 吕虹, 陈燕, 马瑞敏, 张国军. “ESKAPE”在神经外科医源性感染的流行病学研究[J]. 首都医科大学学报, 2017, 38(4): 530-534.
[15]	张继伟, 阎乙夫, 夏溟. 低危前列腺癌¹²⁵I粒子植入治疗尿路合并症的临床分析[J]. 首都医科大学学报, 2017, 38(2): 325-328.